Redx Pharma announces fourth drug development candidate
03 Dec 2015
Redx Pharma is pleased to announce that it has identified a drug development candidate which has the potential to tackle hard-to-treat cancers including pancreatic, triple negative breast and head and neck cancers.
This is the fourth candidate to be advanced from the Company’s innovative development pipeline in the last 12 months. The program has reached development stage in less than two years; as with the other candidates, this is significantly faster than industry averages.
The novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway that is implicated in the maintenance of cancer stem cells in multiple cancer types. These cancer stem cells are associated with tumorigenesis, metastasis, recurrence and resistance in cancer. Of particular significance is the fact that the target also has an emerging role in the field of immuno-oncology with the potential to be combined with checkpoint inhibitors.
The Company will now progress studies to prepare the program for first-in-man clinical trials. Redx believes the superior characteristics of the Company’s compound could result in a best-in-class drug, making the commercial potential for this new development candidate particularly attractive.
Dr Neil Murray, CEO of Redx, said:
We’re delighted to be announcing the fourth drug candidate to make it through our development pipeline. Our novel Porcupine inhibitor has the potential to tackle some of the most hard-to-treat cancers and we are particularly excited by the prospects for this target in immuno-oncology.
We believe this compound has the potential to be a best-in-class therapy that can treat areas of high unmet need. Patients with difficult to treat cancers such as pancreatic, triple negative breast cancer and head and neck cancers could potentially achieve dramatically improved outcomes.
This program has once again demonstrated Redx’s capability to accelerate timelines by taking a candidate to development in less than two years and reflects Redx’s commercially disciplined approach to drug discovery and the quality of its scientific team. We look forward to seeing the program progress over the next 12 months towards first-in-man clinical studies. We have a number of other promising candidates in the pipeline and we’re looking forward to seeing these progress into development in the near future.